Estrogen receptor - Revision history

Michael at 18:27, 30 August 2023

2023-08-30T18:27:04Z

← Older revision		Revision as of 18:27, 30 August 2023
Line 41:		Line 41:
	==See also==		==See also==
	*[[Breast pathology]].		*[[Breast pathology]].
			*[[Tamoxifen]].

	==References==		==References==

Jensflorian: Undo revision 48550 by Jensflorian (talk) -sorry

2018-01-25T09:48:24Z

Undo revision 48550 by Jensflorian (talk) -sorry

← Older revision		Revision as of 09:48, 25 January 2018
Line 1:		Line 1:
	{{ Infobox immunostain		{{ Infobox immunostain
	\| Name = {{PAGENAME}}		\| Name = {{PAGENAME}}
	\| Image =		\| Image = Stomach Metastatic Breast Carcinoma, IHC for Estrogen Receptor (5610737866).jpg
	\| Width =		\| Width =
	\| Caption = ~~PgR~~+ve in metastatic breast carcinoma.		\| Caption = ER+ve in metastatic breast carcinoma.
	\| Abbrev = ~~PgR~~		\| Abbrev = ER
	\| Synonyms =		\| Synonyms =
	\| Similar =		\| Similar =
Line 11:		Line 11:
	\| Subspecial =		\| Subspecial =
	\| Pattern = nuclear staining		\| Pattern = nuclear staining
	\| Positive = Breast carcinoma		\| Positive = Breast and endometrial carcinoma
	\| Negative =		\| Negative =
	\| Other =		\| Other =
	}}		}}

	'''~~Progesterone~~ receptor''', abbreviated '''~~PgR~~''', is a common [[immunostain]].		'''Estrogen receptor''', abbreviated '''ER''', is a common [[immunostain]].

	==General==		==General==
	*Nuclear stain.		*Nuclear stain - like most other "p" stains.
			*In the context of breast pathology it is a [[Quality#Classification_of_IHC_tests\|class II IHC test]], as it is used for treatment decisions by itself.<ref name=pmid20154273>{{Cite journal \| last1 = Torlakovic \| first1 = EE. \| last2 = Riddell \| first2 = R. \| last3 = Banerjee \| first3 = D. \| last4 = El-Zimaity \| first4 = H. \| last5 = Pilavdzic \| first5 = D. \| last6 = Dawe \| first6 = P. \| last7 = Magliocco \| first7 = A. \| last8 = Barnes \| first8 = P. \| last9 = Berendt \| first9 = R. \| title = Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests. \| journal = Am J Clin Pathol \| volume = 133 \| issue = 3 \| pages = 354-65 \| month = Mar \| year = 2010 \| doi = 10.1309/AJCPDYZ1XMF4HJWK \| PMID = 20154273 }}</ref>

	==Positive==		==Positive==
			*Normal breast - usually patchy staining.
			*[[Florid epithelial hyperplasia of the usual type]] - usually patchy staining<ref name=Ref_BP276>{{Ref BP\|276}}</ref> - see ''[[Invasive_breast_cancer#Immunostains_for_typing_and_diagnosis\|immunostains for typing and diagnosis of breast lesions]]''.
	*[[Breast carcinoma]] - most.		*[[Breast carcinoma]] - most.
	*[[~~Meningeoma~~]] - most ~~except for fibromatous subtype.~~<ref>{{~~Cite journal~~ \| ~~last1 = Schnegg~~ \| ~~first1 = JF~~. ~~\| last2 = Gomez \| first2 = F~~. ~~\| last3 = LeMarchand~~-~~Beraud \| first3 = T~~. ~~\| last4 = de Tribolet \| first4 = N. \| title = Presence of sex steroid hormone receptors in meningioma tissue~~. ~~\| journal = Surg Neurol \| volume = 15 \| issue = 6 \| pages = 415~~-~~8 \| month = Jun \| year = 1981 \| doi = \| PMID = 7280951 }}</ref>~~<ref>{{Cite journal \| last1 = ~~Tilzer~~ \| first1 = LL. \| last2 = ~~Plapp~~ \| first2 = FV. \| last3 = ~~Evans~~ \| first3 = JP. \| last4 = ~~Stone~~ \| first4 = D. \| last5 = ~~Alward~~ \| first5 = K. \| title = ~~Steroid~~ receptor ~~proteins~~ in ~~human meningiomas~~. \| journal = ~~Cancer~~ \| volume = 49 \| issue = 4 \| pages = ~~633~~-6 \| month = ~~Feb~~ \| year = ~~1982~~ \| doi = \| PMID = ~~7055777~~ }}</ref>		**[[Ductal carcinoma in situ]] - most, usually diffuse<ref name=Ref_BP276>{{Ref BP\|276}}</ref> - see ''[[Invasive_breast_cancer#Immunostains_for_typing_and_diagnosis\|immunostains for typing and diagnosis of breast lesions]]''.
			**[[Invasive lobular carcinoma]] - all.
			**[[Invasive ductal carcinoma of the breast]] - most.
			*[[Endometrial carcinoma]]s.
			* PRL-producing [[pituitary adenoma]]s (Prolactioma)<ref>{{Cite journal \| last1 = Delgrange \| first1 = E. \| last2 = Vasiljevic \| first2 = A. \| last3 = Wierinckx \| first3 = A. \| last4 = François \| first4 = P. \| last5 = Jouanneau \| first5 = E. \| last6 = Raverot \| first6 = G. \| last7 = Trouillas \| first7 = J. \| title = Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. \| journal = Eur J Endocrinol \| volume = 172 \| issue = 6 \| pages = 791-801 \| month = Jun \| year = 2015 \| doi = 10.1530/EJE-14-0990 \| PMID = 25792376 }}</ref>


	===Occasionally positive===		===Occasionally positive===
	Lung adenocarcinoma.<ref>{{Cite journal \| last1 = ~~Berardi~~ \| first1 = R. \| last2 = ~~Morgese~~ \| first2 = F. \| last3 = ~~Santinelli~~ \| first3 = A. \| last4 = ~~Onofri~~ \| first4 = A. \| last5 = ~~Biscotti~~ \| first5 = T. \| last6 = ~~Brunelli~~ \| first6 = A. \| last7 = ~~Caramanti~~ \| first7 = M. \| last8 = ~~Savini~~ \| first8 = A. \| last9 = ~~De Lisa~~ \| first9 = M. \| title = ~~Hormonal receptors~~ in lung adenocarcinoma~~: expression and difference in outcome by sex~~. \| journal = ~~Oncotarget~~ \| volume = 7 \| issue = 50 \| pages = ~~82648~~-~~82657~~ \| month = ~~Dec~~ \| year = 2016 \| doi = ~~10.18632/oncotarget.12244~~ \| PMID = ~~27690341~~ }}</ref>		*[[Lung adenocarcinoma]] - dependent on the ER subunit target - ERα ~1%, ERβ ~79%.<ref name=pmid27069542>{{Cite journal \| last1 = Tanaka \| first1 = K. \| last2 = Shimizu \| first2 = K. \| last3 = Kakegawa \| first3 = S. \| last4 = Ohtaki \| first4 = Y. \| last5 = Nagashima \| first5 = T. \| last6 = Kaira \| first6 = K. \| last7 = Horiguchi \| first7 = J. \| last8 = Oyama \| first8 = T. \| last9 = Takeyoshi \| first9 = I. \| title = Prognostic significance of aromatase and estrogen receptor beta expression in EGFR wild-type lung adenocarcinoma. \| journal = Am J Transl Res \| volume = 8 \| issue = 1 \| pages = 81-97 \| month = \| year = 2016 \| doi = \| PMID = 27069542 }}</ref>

	==Negative==		==Negative==
			*[[Endocervical adenocarcinoma]].<ref name=pmid20335127>{{Cite journal \| last1 = Hu \| first1 = WW. \| last2 = Tao \| first2 = JH. \| last3 = Li \| first3 = GM. \| last4 = Xu \| first4 = X. \| last5 = Yang \| first5 = XM. \| title = [Value of ER, VIM, CEA and p16 detection in the diagnosis and differential diagnosis of primary endocervical and endometrial adenocarcinomas]. \| journal = Nan Fang Yi Ke Da Xue Xue Bao \| volume = 30 \| issue = 3 \| pages = 526-8, 531 \| month = Mar \| year = 2010 \| doi = \| PMID = 20335127 }}</ref>

	==See also==		==See also==
Line 37:		Line 45:
	{{Reflist\|1}}		{{Reflist\|1}}

	[[Category:Immunohistochemistry~~\|Neuropathology~~]]		[[Category:Immunohistochemistry]]

Jensflorian: created

2018-01-25T09:46:35Z

created

← Older revision		Revision as of 09:46, 25 January 2018
Line 1:		Line 1:
	{{ Infobox immunostain		{{ Infobox immunostain
	\| Name = {{PAGENAME}}		\| Name = {{PAGENAME}}
	\| Image = ~~Stomach Metastatic Breast Carcinoma, IHC for Estrogen Receptor (5610737866).jpg~~		\| Image =
	\| Width =		\| Width =
	\| Caption = ER+ve in metastatic breast carcinoma.		\| Caption = PgR+ve in metastatic breast carcinoma.
	\| Abbrev = ER		\| Abbrev = PgR
	\| Synonyms =		\| Synonyms =
	\| Similar =		\| Similar =
Line 11:		Line 11:
	\| Subspecial =		\| Subspecial =
	\| Pattern = nuclear staining		\| Pattern = nuclear staining
	\| Positive = Breast ~~and endometrial~~ carcinoma		\| Positive = Breast carcinoma
	\| Negative =		\| Negative =
	\| Other =		\| Other =
	}}		}}

	'''~~Estrogen~~ receptor''', abbreviated '''ER''', is a common [[immunostain]].		'''Progesterone receptor''', abbreviated '''PgR''', is a common [[immunostain]].

	==General==		==General==
	*Nuclear stain ~~- like most other "p" stains~~.		*Nuclear stain.
	*In the context of breast pathology it is a [[Quality#Classification_of_IHC_tests\|class II IHC test]], as it is used for treatment decisions by itself.<ref name=pmid20154273>{{Cite journal \| last1 = Torlakovic \| first1 = EE. \| last2 = Riddell \| first2 = R. \| last3 = Banerjee \| first3 = D. \| last4 = El-Zimaity \| first4 = H. \| last5 = Pilavdzic \| first5 = D. \| last6 = Dawe \| first6 = P. \| last7 = Magliocco \| first7 = A. \| last8 = Barnes \| first8 = P. \| last9 = Berendt \| first9 = R. \| title = Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests. \| journal = Am J Clin Pathol \| volume = 133 \| issue = 3 \| pages = 354-65 \| month = Mar \| year = 2010 \| doi = 10.1309/AJCPDYZ1XMF4HJWK \| PMID = 20154273 }}</ref>

	==Positive==		==Positive==
	*Normal breast - usually patchy staining.
	*[[Florid epithelial hyperplasia of the usual type]] - usually patchy staining<ref name=Ref_BP276>{{Ref BP\|276}}</ref> - see ''[[Invasive_breast_cancer#Immunostains_for_typing_and_diagnosis\|immunostains for typing and diagnosis of breast lesions]]''.
	*[[Breast carcinoma]] - most.		*[[Breast carcinoma]] - most.
	**[[~~Ductal carcinoma in situ~~]] - most~~, usually diffuse~~<ref ~~name=Ref_BP276~~>{{~~Ref BP~~\|~~276}}</ref>~~ - ~~see ''[[Invasive_breast_cancer#Immunostains_for_typing_and_diagnosis~~\|~~immunostains for typing and diagnosis of breast lesions]]''~~.		*[[Meningeoma]] - most except for fibromatous subtype.<ref>{{Cite journal \| last1 = Schnegg \| first1 = JF. \| last2 = Gomez \| first2 = F. \| last3 = LeMarchand-Beraud \| first3 = T. \| last4 = de Tribolet \| first4 = N. \| title = Presence of sex steroid hormone receptors in meningioma tissue. \| journal = Surg Neurol \| volume = 15 \| issue = 6 \| pages = 415-8 \| month = Jun \| year = 1981 \| doi = \| PMID = 7280951 }}</ref><ref>{{Cite journal \| last1 = Tilzer \| first1 = LL. \| last2 = Plapp \| first2 = FV. \| last3 = Evans \| first3 = JP. \| last4 = Stone \| first4 = D. \| last5 = Alward \| first5 = K. \| title = Steroid receptor proteins in human meningiomas. \| journal = Cancer \| volume = 49 \| issue = 4 \| pages = 633-6 \| month = Feb \| year = 1982 \| doi = \| PMID = 7055777 }}</ref>
	**[[Invasive lobular carcinoma]] - all.
	**[[Invasive ductal carcinoma of ~~the breast]] - most~~.
	*[[Endometrial carcinoma]]s.
	* PRL-~~producing [[pituitary adenoma]]s (Prolactioma)~~<ref>{{Cite journal \| last1 = ~~Delgrange~~ \| first1 = E. \| last2 = ~~Vasiljevic~~ \| first2 = A. \| last3 = ~~Wierinckx~~ \| first3 = A. \| last4 = ~~François~~ \| first4 = P. \| last5 = ~~Jouanneau~~ \| first5 = ~~E. \| last6 = Raverot \| first6 = G. \| last7 = Trouillas \| first7 = J~~. \| title = ~~Expression of estrogen~~ receptor ~~alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference~~ in ~~tumor growth~~. \| journal = ~~Eur J Endocrinol~~ \| volume = ~~172~~ \| issue = 6 \| pages = ~~791~~-~~801~~ \| month = ~~Jun~~ \| year = ~~2015~~ \| doi = ~~10.1530/EJE-14-0990~~ \| PMID = ~~25792376~~ }}</ref>


	===Occasionally positive===		===Occasionally positive===
	*[[Lung adenocarcinoma~~]] - dependent on the ER subunit target - ERα ~1%, ERβ ~79%~~.<ref ~~name=pmid27069542~~>{{Cite journal \| last1 = ~~Tanaka~~ \| first1 = K. \| last2 = ~~Shimizu~~ \| first2 = K. \| last3 = ~~Kakegawa~~ \| first3 = S. \| last4 = ~~Ohtaki~~ \| first4 = Y. \| last5 = ~~Nagashima~~ \| first5 = T. \| last6 = ~~Kaira~~ \| first6 = K. \| last7 = ~~Horiguchi~~ \| first7 = J. \| last8 = ~~Oyama~~ \| first8 = T. \| last9 = ~~Takeyoshi~~ \| first9 = I. \| title = ~~Prognostic significance of aromatase and estrogen receptor beta expression~~ in ~~EGFR wild-type~~ lung adenocarcinoma. \| journal = ~~Am J Transl Res~~ \| volume = 8 \| issue = 1 \| pages = 81-97 \| month = \| year = 2016 \| doi = \| PMID = ~~27069542~~ }}</ref>		Lung adenocarcinoma.<ref>{{Cite journal \| last1 = Berardi \| first1 = R. \| last2 = Morgese \| first2 = F. \| last3 = Santinelli \| first3 = A. \| last4 = Onofri \| first4 = A. \| last5 = Biscotti \| first5 = T. \| last6 = Brunelli \| first6 = A. \| last7 = Caramanti \| first7 = M. \| last8 = Savini \| first8 = A. \| last9 = De Lisa \| first9 = M. \| title = Hormonal receptors in lung adenocarcinoma: expression and difference in outcome by sex. \| journal = Oncotarget \| volume = 7 \| issue = 50 \| pages = 82648-82657 \| month = Dec \| year = 2016 \| doi = 10.18632/oncotarget.12244 \| PMID = 27690341 }}</ref>

	==Negative==		==Negative==
	*[[Endocervical adenocarcinoma]].<ref name=pmid20335127>{{Cite journal \| last1 = Hu \| first1 = WW. \| last2 = Tao \| first2 = JH. \| last3 = Li \| first3 = GM. \| last4 = Xu \| first4 = X. \| last5 = Yang \| first5 = XM. \| title = [Value of ER, VIM, CEA and p16 detection in the diagnosis and differential diagnosis of primary endocervical and endometrial adenocarcinomas]. \| journal = Nan Fang Yi Ke Da Xue Xue Bao \| volume = 30 \| issue = 3 \| pages = 526-8, 531 \| month = Mar \| year = 2010 \| doi = \| PMID = 20335127 }}</ref>

	==See also==		==See also==
Line 45:		Line 37:
	{{Reflist\|1}}		{{Reflist\|1}}

	[[Category:Immunohistochemistry]]		[[Category:Immunohistochemistry\|Neuropathology]]

Jensflorian: +infobox

2018-01-25T09:32:55Z

+infobox

← Older revision		Revision as of 09:32, 25 January 2018
Line 1:		Line 1:
			{{ Infobox immunostain
			\| Name = {{PAGENAME}}
			\| Image = Stomach Metastatic Breast Carcinoma, IHC for Estrogen Receptor (5610737866).jpg
			\| Width =
			\| Caption = ER+ve in metastatic breast carcinoma.
			\| Abbrev = ER
			\| Synonyms =
			\| Similar =
			\| Clones =
			\| Use =
			\| Subspecial =
			\| Pattern = nuclear staining
			\| Positive = Breast and endometrial carcinoma
			\| Negative =
			\| Other =
			}}

	'''Estrogen receptor''', abbreviated '''ER''', is a common [[immunostain]].		'''Estrogen receptor''', abbreviated '''ER''', is a common [[immunostain]].

Jensflorian: /* Positive */ +Prolactioma

2018-01-25T09:24:24Z

Positive: +Prolactioma

← Older revision		Revision as of 09:24, 25 January 2018
Line 13:		Line 13:
	**[[Invasive ductal carcinoma of the breast]] - most.		**[[Invasive ductal carcinoma of the breast]] - most.
	*[[Endometrial carcinoma]]s.		*[[Endometrial carcinoma]]s.
			* PRL-producing [[pituitary adenoma]]s (Prolactioma)<ref>{{Cite journal \| last1 = Delgrange \| first1 = E. \| last2 = Vasiljevic \| first2 = A. \| last3 = Wierinckx \| first3 = A. \| last4 = François \| first4 = P. \| last5 = Jouanneau \| first5 = E. \| last6 = Raverot \| first6 = G. \| last7 = Trouillas \| first7 = J. \| title = Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. \| journal = Eur J Endocrinol \| volume = 172 \| issue = 6 \| pages = 791-801 \| month = Jun \| year = 2015 \| doi = 10.1530/EJE-14-0990 \| PMID = 25792376 }}</ref>


	===Occasionally positive===		===Occasionally positive===

Michael: /* Positive */

2016-06-23T20:41:28Z

Positive

← Older revision		Revision as of 20:41, 23 June 2016
Line 7:		Line 7:
	==Positive==		==Positive==
	*Normal breast - usually patchy staining.		*Normal breast - usually patchy staining.
	*[[Florid epithelial hyperplasia of the usual type]] - usually patchy staining.<ref name=Ref_BP276>{{Ref BP\|276}}</ref>		*[[Florid epithelial hyperplasia of the usual type]] - usually patchy staining<ref name=Ref_BP276>{{Ref BP\|276}}</ref> - see ''[[Invasive_breast_cancer#Immunostains_for_typing_and_diagnosis\|immunostains for typing and diagnosis of breast lesions]]''.
	*[[Breast carcinoma]] - most.		*[[Breast carcinoma]] - most.
	**[[Ductal carcinoma in situ]] - most, usually diffuse.<ref name=Ref_BP276>{{Ref BP\|276}}</ref>		**[[Ductal carcinoma in situ]] - most, usually diffuse<ref name=Ref_BP276>{{Ref BP\|276}}</ref> - see ''[[Invasive_breast_cancer#Immunostains_for_typing_and_diagnosis\|immunostains for typing and diagnosis of breast lesions]]''.
	**[[Invasive lobular carcinoma]] - all.		**[[Invasive lobular carcinoma]] - all.
	**[[Invasive ductal carcinoma of the breast]] - most.		**[[Invasive ductal carcinoma of the breast]] - most.

Michael: /* Positive */

2016-06-23T20:39:15Z

Positive

← Older revision		Revision as of 20:39, 23 June 2016
Line 6:		Line 6:

	==Positive==		==Positive==
			*Normal breast - usually patchy staining.
			*[[Florid epithelial hyperplasia of the usual type]] - usually patchy staining.<ref name=Ref_BP276>{{Ref BP\|276}}</ref>
	*[[Breast carcinoma]] - most.		*[[Breast carcinoma]] - most.
	**[[Ductal carcinoma in situ]] - most.		**[[Ductal carcinoma in situ]] - most, usually diffuse.<ref name=Ref_BP276>{{Ref BP\|276}}</ref>
	**[[Invasive lobular carcinoma]] - all.		**[[Invasive lobular carcinoma]] - all.
	**[[Invasive ductal carcinoma of the breast]] - most.		**[[Invasive ductal carcinoma of the breast]] - most.

Michael: /* General */

2016-06-23T20:35:30Z

General

← Older revision		Revision as of 20:35, 23 June 2016
Line 2:		Line 2:

	==General==		==General==
	In the context of breast pathology it is a [[Quality#Classification_of_IHC_tests\|class II IHC test]], as it is used for treatment decisions by itself.<ref name=pmid20154273>{{Cite journal \| last1 = Torlakovic \| first1 = EE. \| last2 = Riddell \| first2 = R. \| last3 = Banerjee \| first3 = D. \| last4 = El-Zimaity \| first4 = H. \| last5 = Pilavdzic \| first5 = D. \| last6 = Dawe \| first6 = P. \| last7 = Magliocco \| first7 = A. \| last8 = Barnes \| first8 = P. \| last9 = Berendt \| first9 = R. \| title = Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests. \| journal = Am J Clin Pathol \| volume = 133 \| issue = 3 \| pages = 354-65 \| month = Mar \| year = 2010 \| doi = 10.1309/AJCPDYZ1XMF4HJWK \| PMID = 20154273 }}</ref>		*Nuclear stain - like most other "p" stains.
			*In the context of breast pathology it is a [[Quality#Classification_of_IHC_tests\|class II IHC test]], as it is used for treatment decisions by itself.<ref name=pmid20154273>{{Cite journal \| last1 = Torlakovic \| first1 = EE. \| last2 = Riddell \| first2 = R. \| last3 = Banerjee \| first3 = D. \| last4 = El-Zimaity \| first4 = H. \| last5 = Pilavdzic \| first5 = D. \| last6 = Dawe \| first6 = P. \| last7 = Magliocco \| first7 = A. \| last8 = Barnes \| first8 = P. \| last9 = Berendt \| first9 = R. \| title = Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests. \| journal = Am J Clin Pathol \| volume = 133 \| issue = 3 \| pages = 354-65 \| month = Mar \| year = 2010 \| doi = 10.1309/AJCPDYZ1XMF4HJWK \| PMID = 20154273 }}</ref>

	==Positive==		==Positive==

Michael: /* Negative */

2016-06-23T20:34:38Z

Negative

← Older revision		Revision as of 20:34, 23 June 2016
Line 15:		Line 15:

	==Negative==		==Negative==
	*[[Endocervical adenocarcinoma]].		*[[Endocervical adenocarcinoma]].<ref name=pmid20335127>{{Cite journal \| last1 = Hu \| first1 = WW. \| last2 = Tao \| first2 = JH. \| last3 = Li \| first3 = GM. \| last4 = Xu \| first4 = X. \| last5 = Yang \| first5 = XM. \| title = [Value of ER, VIM, CEA and p16 detection in the diagnosis and differential diagnosis of primary endocervical and endometrial adenocarcinomas]. \| journal = Nan Fang Yi Ke Da Xue Xue Bao \| volume = 30 \| issue = 3 \| pages = 526-8, 531 \| month = Mar \| year = 2010 \| doi = \| PMID = 20335127 }}</ref>

	==See also==		==See also==

Michael: /* Positive */

2016-06-23T20:31:52Z

Positive

← Older revision		Revision as of 20:31, 23 June 2016
Line 10:		Line 10:
	**[[Invasive ductal carcinoma of the breast]] - most.		**[[Invasive ductal carcinoma of the breast]] - most.
	*[[Endometrial carcinoma]]s.		*[[Endometrial carcinoma]]s.

			===Occasionally positive===
			*[[Lung adenocarcinoma]] - dependent on the ER subunit target - ERα ~1%, ERβ ~79%.<ref name=pmid27069542>{{Cite journal \| last1 = Tanaka \| first1 = K. \| last2 = Shimizu \| first2 = K. \| last3 = Kakegawa \| first3 = S. \| last4 = Ohtaki \| first4 = Y. \| last5 = Nagashima \| first5 = T. \| last6 = Kaira \| first6 = K. \| last7 = Horiguchi \| first7 = J. \| last8 = Oyama \| first8 = T. \| last9 = Takeyoshi \| first9 = I. \| title = Prognostic significance of aromatase and estrogen receptor beta expression in EGFR wild-type lung adenocarcinoma. \| journal = Am J Transl Res \| volume = 8 \| issue = 1 \| pages = 81-97 \| month = \| year = 2016 \| doi = \| PMID = 27069542 }}</ref>

	==Negative==		==Negative==